OncoMatch/Clinical Trials/NCT07691606
A Study of ARC-02 in B-cell NHL
Is NCT07691606 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies multiple treatments including ARC-02 and Rituximab for b-cell non hodgkin lymphoma.
Treatment: ARC-02 · Rituximab — This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
Received at least 2 prior lines of systemic therapies and not eligible to receive additional standard of care therapies
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function within 3 days of the first dose of study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Start Cala · Los Angeles, California
- Norton Cancer Institute · Louisville, Kentucky
- NYU Langone · New York, New York
- Levine Cancer Institute · Charlotte, North Carolina
- Massey Cancer Center · Richmond, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07691606 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages